Effects of Cryotherapy on Objective and Subjective Symptoms of Paclitaxel-Induced Neuropathy: Prospective Self-Controlled Trial

Akiko Hanai, Hiroshi Ishiguro, Takashi Sozu, Moe Tsuda, Ikuko Yano, Takayuki Nakagawa, Satoshi Imai, Yoko Hamabe, Masakazu Toi, Hidenori Arai, Tadao Tsuboyama, Akiko Hanai, Hiroshi Ishiguro, Takashi Sozu, Moe Tsuda, Ikuko Yano, Takayuki Nakagawa, Satoshi Imai, Yoko Hamabe, Masakazu Toi, Hidenori Arai, Tadao Tsuboyama

Abstract

Background: Chemotherapy-induced peripheral neuropathy (CIPN) is a dose-limiting and disabling side effect of taxane anticancer agents. We prospectively evaluated the efficacy of cryotherapy for CIPN prevention.

Methods: Breast cancer patients treated weekly with paclitaxel (80 mg/m2 for one hour) wore frozen gloves and socks on the dominant side for 90 minutes, including the entire duration of drug infusion. Symptoms on the treated sides were compared with those on the untreated (nondominant) sides. The primary end point was CIPN incidence assessed by changes in tactile sensitivity from pretreatment baseline in a monofilament test at a cumulative dose of 960 mg/m2. We also assessed thermosensory deficits, subjective symptoms (Patient Neuropathy Questionnaire [PNQ]), manipulative dexterity, and the time to events and hazard ratio by PNQ. All statistical tests were two-sided.

Results: Among the 40 patients, four did not reach the cumulative dose (due to the occurrence of pneumonia, severe fatigue, severe liver dysfunction, and macular edema), leaving 36 patients for analysis. None dropped out due to cold intolerance. The incidence of objective and subjective CIPN signs was clinically and statistically significantly lower on the intervention side than on the control (hand: tactile sensitivity = 27.8% vs 80.6%, odds ratio [OR] = 20.00, 95% confidence interval [CI] = 3.20 to 828.96, P < .001; foot: tacile sensitivity = 25.0% vs 63.9%, OR = infinite, 95% CI = 3.32 to infinite, P < .001; hand: warm sense = 8.8% vs 32.4%, OR = 9.00, 95% CI = 1.25 to 394.48, P = .02; foot: warm sense: 33.4% vs 57.6%, OR = 5.00, 95% CI = 1.07 to 46.93, P = .04; hand: PNQ = 2.8% vs 41.7%, OR = infinite, 95% CI = 3.32 to infinite, P < .001; foot: PNQ = 2.8% vs 36.1%, OR = infinite, 95% CI = 2.78 to infinite, P < .001; hand: hazard ratio [HR] = 0.13, 95% CI = 0.05 to 0.34; foot: HR = 0.13, 95% CI = 0.04 to 0.38, dexterity mean delay = -2.5 seconds, SD = 12.0 seconds, vs + 8.6 seconds, SD = 25.8 seconds, P = .005).

Conclusions: Cryotherapy is useful for preventing both the objective and subjective symptoms of CIPN and resultant dysfunction.

Figures

Figure 1.
Figure 1.
Study flow diagram. We included 40 patients who received the allocated intervention and analyzed the cumulative dose for subjective chemotherapy-induced peripheral neuropathy (CIPN) events. All CIPN signs were analyzed in the 36 patients who reached a cumulative dose of 960 mg/m2. We compared the hands and feet of the intervention side to those of the control side.
Figure 2.
Figure 2.
Objective chemotherapy-induced peripheral neuropathy (CIPN) events at a cumulative dose of 960 mg/m2. A) The efficacy of cryotherapy for reducing the primary end point, incidence of CIPN, was assessed by tactile-sensory deficits on the monofilament test. Any tactile deterioration from the pretreatment baseline in an intervention or control side hand or foot at a cumulative dose of 960 mg/m2 was considered a CIPN event. The differential incidence between the intervention and control sides was evaluated using a two-sided McNemar’s test (n = 36). B) Treatment with cryotherapy reduced thermosensory dysfunction. Only patients who exhibited a normal sensory threshold at baseline were included (hand: warm, n = 34, cold, n = 36; foot: warm, n = 33, cold, n = 32). Any response delay, response reduction, or thermal analgesia at a cumulative dose of 960 mg/ m2 was considered a CIPN. C) This figure shows manipulative dexterity deficits. P values were determined by a two-sided paired t test between the intervention and control side. The solid line denotes the intervention side, and the dotted line indicates the control side (N = 36).
Figure 3.
Figure 3.
Severity of subjective symptoms (at a cumulative dose of 960 mg/m2). The administration of cryotherapy also reduced the subjective symptoms based on the Patient Neuropathy Questionnaire responses (the secondary end point, subjective) at a cumulative dose of 960 mg/m2 (P values determined by the McNemar’s test, n = 36). The subjective responses to each item were graded from A (no neuropathy) to E (severe neuropathy) by the patient. A rank of D or E indicates impaired activities of daily living. *Activities of daily living were interfered with.
Figure 4.
Figure 4.
The appearance of severe subjective neuropathy symptoms with cumulative dose. Severe subjective neuropathy symptoms (Patient Neuropathy Questionnaire ≥ D; moderate to severe tingling, pain, or numbness that interferes with activities of daily living) with cumulative dose were compared between the intervention and control sides using a log-rank test (n = 40). The solid line denotes the intervention side, and the dotted line indicates the control side. The dotted vertical line represents a cumulative dose of 960 mg/m2. We included four censored patients who did not complete cumulative dose of 960 mg/m2 paclitaxel due to pneumonia (n = 1), severe fatigue (n = 1), severe liver dysfunction (n = 1), and macular edema (n = 1). A two-sided log-rank test was used to calculate the P values.
Figure 5.
Figure 5.
Cumulative dose to subjective symptoms (Patient Neuropathy Questionnaire rank ≥ D; moderate to severe tingling, pain, or numbness that interferes with activities of daily living [ADL]) on the control side to identify chemotherapy-induced peripheral neuropathy (CIPN) risk factors (n = 40). A) This figure presents the high/low area under the curve (AUC; µg·h/mL). The low-AUC group (mean = 6.6 µg·h/mL, SD = 0.5µg·h/mL) and high-AUC group (mean = 8.3 µg·h/mL, SD = 1.4 µg·h/mL) were divided by the median AUC (7.2 µg·h/mL). The solid line denotes the high-AUC group, and the dotted line indicates the low-AUC group. B) This figure presents high/low dose intensity (mg/m2/wk). The low–dose intensity group (mean = 56.6 mg/m2/wk, SD = 6.7 mg/m2/wk) and high–dose intensity group (mean = 75.0 mg/m2/wk, SD = 4.8 mg/m2/wk) were divided by the median dose intensity (68.6 mg/ m2/wk). The solid line represents the high–dose intensity group, and the dotted line denotes the low–dose intensity group. A two-sided log-rank test was used to calculate the P values.

References

    1. Cavaletti G, Marmiroli P.. Chemotherapy-induced peripheral neurotoxicity. Nat Rev Neurol. 2010;6(12):657–666.
    1. Mols F, Beijers T, Vreugdenhil G, van de Poll-Franse L.. Chemotherapy-induced peripheral neuropathy and its association with quality of life: A systematic review. Support Care Cancer. 2014;22(8):2261–2269.
    1. Speck RM, Sammel MD, Farrar JT, et al. . Impact of chemotherapy-induced peripheral neuropathy on treatment delivery in nonmetastatic breast cancer. J Oncol Pract. 2013;9(5):e234–e240.
    1. Hershman DL, Lacchetti C, Dworkin RH, et al. . Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2014;32(18):1941–1967.
    1. Smith EML, Pang H, Cirrincione C, et al. . Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: A randomized clinical trial. JAMA. 2013;309(13):1359–1367.
    1. Kadakia KC, Rozell SA, Butala AA, Loprinzi CL.. Supportive cryotherapy: A review from head to toe. J Pain Symptom Manage. 2014;47(6):1100–1115.
    1. Scotté F, Banu E, Medioni J, et al. . Matched case-control phase 2 study to evaluate the use of a frozen sock to prevent docetaxel-induced onycholysis and cutaneous toxicity of the foot. Cancer. 2008;112(7):1625–1631.
    1. Scotté F, Tourani J-M, Banu E, et al. . Multicenter study of a frozen glove to prevent docetaxel-induced onycholysis and cutaneous toxicity of the hand. J Clin Oncol. 2005;23(19):4424–4429.
    1. Eckhoff L, Knoop AS, Jensen M-B, Ejlertsen B, Ewertz M.. Risk of docetaxel-induced peripheral neuropathy among 1,725 Danish patients with early stage breast cancer. Breast Cancer Res Treat. 2013;142(1):109–118.
    1. Alberti P, Rossi E, Cornblath DR, et al. . Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: Two sides of the same coin. Ann Oncol. 2014;25(1):257–264.
    1. Shimozuma K, Ohashi Y, Takeuchi A, et al. . Feasibility and validity of the Patient Neurotoxicity Questionnaire during taxane chemotherapy in a phase III randomized trial in patients with breast cancer: N-SAS BC 02. Support Care Cancer. 2009;17(12):1483–1491.
    1. Sparano JA, Wang M, Martino S, et al. . Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med. 2008;358(16):1663–1671.
    1. Jayaprakash P, Bhansali A, Bhansali S, et al. . Validation of bedside methods in evaluation of diabetic peripheral neuropathy. Indian J Med Res. 2011;133(6):645–649.
    1. Dougherty PM, Cata JP, Cordella J V, Burton A, Weng H-R.. Taxol-induced sensory disturbance is characterized by preferential impairment of myelinated fiber function in cancer patients. Pain. 2004;109(1–2):132–142.
    1. Bryden PJ, Roy EA.. A new method of administering the Grooved Pegboard Test: Performance as a function of handedness and sex. Brain Cogn. 2005;58(3):258–268.
    1. Kimura J. Electrodiagnosis in Diseases of Nerve and Muscle: Principles and Practice. 4th ed.Oxford: Oxford University Press; 2013.
    1. Neuval Database II–Normative Data. Neurometer CPT Sensory Nerve Conduction Threshold Current Perception Threshold Test (sNCT/CPT). 2004. . Accessed September 10, 2016.
    1. Onoue H, Yano I, Tanaka A, et al. . Significant effect of age on docetaxel pharmacokinetics in Japanese female breast cancer patients by using the population modeling approach. Eur J Clin Pharmacol. 2016;72(6):703–710.
    1. Huizenga C, Zhang H, Arens E, Wang D.. Skin and core temperature response to partial- and whole-body heating and cooling. J Therm Biol. 2004;29(7):549–558.
    1. Zhang J, Tuckett RP.. Comparison of paclitaxel and cisplatin effects on the slowly adapting type I mechanoreceptor. Brain Res. 2008;1214:50–57.
    1. Park SB, Goldstein D, Krishnan A V, et al. . Chemotherapy-induced peripheral neurotoxicity: A critical analysis. CA Cancer J Clin. 2013;63(6):419–437.
    1. Tsuyuki S, Senda N, Kanng Y, et al. . Evaluation of the effect of compression therapy using surgical gloves on nanoparticle albumin-bound paclitaxel-induced peripheral neuropathy: A phase II multicenter study by the Kamigata Breast Cancer Study Group. Breast Cancer Res Treat. 2016;160(1):61–67.
    1. Bennett GJ, Liu GK, Xiao WH, Jin HW, Siau C.. Terminal arbor degeneration—a novel lesion produced by the antineoplastic agent paclitaxel. Eur J Neurosci. 2011;33(9):1667–1676.
    1. Mielke S, Sparreboom A, Steinberg SM, et al. . Association of paclitaxel pharmacokinetics with the development of peripheral neuropathy in patients with advanced cancer. Clin Cancer Res. 2005;11(13):4843–4850.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren